Evidence map›Paper›PMID 28117835›Full record

ArticleNature communications2017

Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.

Bai-Yu Lee, Daniel L Clemens, Aleidy Silva, Barbara Jane Dillon, Saša Masleša-Galić, Susana Nava, Xianting Ding, Chih-Ming Ho, Marcus A Horwitz

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03561753 (Pilot Clinical Trial of PRS TB Regimen I - Phase II), which is not on this map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03561753 phase4completednot on this map

Pilot Clinical Trial of PRS TB Regimen I - Phase II

TypeinterventionalSponsorShanghai Pulmonary Hospital, Shanghai, ChinaRan2017 to 2020Enrolled97ConditionsPulmonary Tuberculosis TB in Sputum: (+) MicroscopyArmsGroup A (the standard 2HRZE/4HR regimen）, Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Trial
  3. ComparativeMicrobiology spectrum · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Clofazimine for the treatment of tuberculosis.Frontiers in pharmacology · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Bai-Yu LeeDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, California 90095, USA.
Daniel L ClemensDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, California 90095, USA.
Aleidy SilvaDepartment of Mechanical and Aerospace Engineering, University of California, Los Angeles, California 90095, USA.
Barbara Jane DillonDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, California 90095, USA.
Saša Masleša-GalićDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, California 90095, USA.
Susana NavaDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, California 90095, USA.
Xianting DingMed-X Research Institute, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Chih-Ming HoDepartment of Mechanical and Aerospace Engineering, University of California, Los Angeles, California 90095, USA.
Marcus A HorwitzDivision of Infectious Diseases, Department of Medicine, University of California, Los Angeles, California 90095, USA.
University of California, Los Angeles · USShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current drug regimens for treating tuberculosis are lengthy and onerous, and hence complicated by poor adherence leading to drug resistance and disease relapse. Previously, using an output-driven optimization platform and an in vitro macrophage model of Mycobacterium tuberculosis infection, we identified several experimental drug regimens among billions of possible drug-dose combinations that outperform the current standard regimen. Here we use this platform to optimize the in vivo drug doses of two of these regimens in a mouse model of pulmonary tuberculosis. The experimental regimens kill M. tuberculosis much more rapidly than the standard regimen and reduce treatment time to relapse-free cure by 75%. Thus, these regimens have the potential to provide a markedly shorter course of treatment for tuberculosis in humans. As these regimens omit isoniazid, rifampicin, fluoroquinolones and injectable aminoglycosides, they would be suitable for treating many cases of multidrug and extensively drug-resistant tuberculosis.

Indexed as

AnimalsAntitubercular AgentsColony Count, MicrobialDisease Models, AnimalDose-Response Relationship, DrugDrug InteractionsDrug Therapy, CombinationFemaleHumansMedication AdherenceMiceMice, Inbred BALB CMycobacterium tuberculosisSpecific Pathogen-Free OrganismsTime FactorsTreatment OutcomeAntitubercular Agents

Identifiers

PMID28117835
PMCPMC5287291
OpenAlexW2582313469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.